Bangladesh Pharmaceuticals and Healthcare Report Q4 2012

  • ID: 2254718
  • October 2012
  • Region: Bangladesh
  • 91 pages
  • Business Monitor International
1 of 3

The Bangladesh Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Bangladesh's pharmaceuticals and healthcare industry.

BMI View:

While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies, such as Bangladesh, may be a favourable strategy for any multinational pharmaceutical company – it is vital that a company recognises both the rewards and the risks present in a market. With regards to assessing risks in the Bangladeshi healthcare sector, we have identified those emanating from the state’s political/economic profile (such as high inflation) and industry specific dangers (such as low per-capita spending and poor access to healthcare facilities) that call into question the likelihood of anticipated returns being realised over the assessed time period.

Headline Expenditure Projections

- Pharmaceuticals: BDT111.10bn (US$1.50bn) in 2011 to BDT124.15bn (US$1.52bn) in 2012;
+11.7% in local currency terms READ MORE >

Note: Product cover images may vary from those shown
2 of 3

Executive Summary 5

SWOT Analysis 7

Bangladesh Pharmaceuticals And Healthcare Industry SWOT 7

Bangladesh Political SWOT 8

Bangladesh Economic SWOT 8

Bangladesh Business Environment SWOT 9

Pharmaceutical Risk/Reward Ratings 10
Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q412 10

Rewards 11

Risks 12

Bangladesh – Market Summary 13

Regulatory Regime 14
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence 15

Counterfeit Drugs 16

Intellectual Property 17

Pricing And Reimbursement Regime 18

International Collaboration 19

Industry Developments 21

Epidemiology 21

Communicable Diseases 22

Non-Communicable Diseases 25

Healthcare Sector 26

Healthcare Sector Provision 29

Healthcare Sector Financing 30

Research & Development 31
Table: Suggestions Made By University Of Dhaka’s Faculty Of Pharmacy To Improve Pharmaceutical Research 32

Clinical Trials 33

Medical Devices 33

Industry Forecast Scenario 35

Overall Market Forecast 35
Table: Pharmaceutical Sales Indicators 2008-2016 36

Key Growth Factors – Industry 37
Table: Healthcare Expenditure Indicators, 2008-2016 38
Table: Healthcare Governmental Indicators, 2008-2016 38
Table: Healthcare Private Indicators, 2008-2016 39

Key Growth Factors – Macroeconomic 40
Table: Bangladesh - Economic Activity, 2011-2016 46

Prescription Drug Market Forecast 47
Table: Prescription Drug Sales Indicators, 2008-2016 48

Patented Drug Market Forecast 49
Table: Patented Drug Market Indicators, 2008-2016 49

Generic Drug Market Forecast 50
Table: Generic Drug Sales Indicators, 2008-2016 50

Bangladesh Pharmaceuticals & Healthcare Report Q412

© Business Monitor International Ltd

Page 4

OTC Medicine Market Forecast 51
Table: OTC Medicine Sales Indicators, 2008-2016 52

Pharmaceutical Trade Forecast 53
Table: Exports and Imports Indicators, 2008-2016 55

Medical Devices Market Forecast 56
Table: Medical Devices Sales Indicators 2008-2016 57

Other Healthcare Data Forecasts 58

Key Risks To BMI’s Forecasts 58

Competitive Landscape 59

Pharmaceutical Industry 59

Domestic Pharmaceutical Industry 60

Foreign Pharmaceutical Industry 60

Contract Manufacturing 61

Foreign Company Developments 63

Local Company Developments 64

Pharmaceutical Distribution 66

Company Profiles 67

Local Companies 67

Eskayef Bangladesh 67

Square Pharmaceuticals 69

Renata 72

Beximco Pharmaceuticals 74

Multinational Companies 77

Sanofi 77

Novartis 79

Demographic Outlook 81
Table: Population By Age Group, 1990-2020 (‘000) 82
Table: Bangladesh’s Population By Age Group, 1990-2020 (% of total) 83
Table: Key Population Ratios, 1990-2020 84
Table: Rural/Urban Population Split, 1990-2020 84

Glossary 85

BMI Methodology 87

How We Generate Our Pharmaceutical Industry Forecasts 87

Pharmaceutical Risk/Reward Ratings Methodology 88

Ratings Overview 88
Table: Pharmaceutical Risk/Reward Indicators 89

Weighting 90
Table: Weighting Of Components 90

Sources 90

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S